MEI6570

Phase 2Biologic

NNational Heart Centre Singapore

MEI6570 is one of 34 biologic programs targeting Peripheral Arterial Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Arterial DiseaseActive, not recruiting

Peripheral Arterial DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Peripheral Arterial Disease

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

8 2

Plavix

Sanofi

Approved

6 3

Brilinta

AstraZeneca

Approved

2 4

Praluent

Regeneron

Approved

1 5

Zyloprim

Jazz Pharmaceuticals

Approved

1 6

Colcrys

Zetia

2 8

Pletal

Otsuka

Approved

2 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Torisel

PPrism Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peripheral Arterial Disease1 trial

REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD

Active, not recruiting·NNational Heart Centre Singapore·Phase 2·NCT05912218·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MEI6570. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEI6570 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEI6570. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart Centre Singapore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Heart Centre Singapore

MEI6570

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peripheral Arterial Disease1 trial

References

Drug Info

Quick Facts

Related News